Insulin resistance has been associated with PD in several studies, and PTBP1 modulates the expression of glucagon-like peptide 1 (GLP-1) [98], which constitutes a pharmacological target in clinical trials for PD [99]. Here, PTBP1 is linked to Parkinson disease.